Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Estrella Immunopharma, Inc. (ESLA) had Income from Continuous Operations of $-7.31M for the most recently reported fiscal year, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
$-7.31M |
|
-- |
|
-- |
|
$7.31M |
|
$-7.31M |
|
-- |
|
$-7.31M |
|
$-7.31M |
|
$-7.31M |
|
|
Income from Continuous Operations |
$-7.31M |
$-7.31M |
|
$-7.31M |
|
$-7.31M |
|
$-7.31M |
|
27.10M |
|
27.10M |
|
$-0.27 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$4.45M |
|
-- |
|
-- |
|
$4.45M |
|
$0.18M |
|
-- |
|
-- |
|
$0.18M |
|
$4.27M |
|
$4.27M |
|
$4.27M |
|
36.29M |
|
| Cash Flow Statement Financials | |
$-16.07M |
|
$4.96M |
|
$12.79M |
|
$2.48M |
|
$4.17M |
|
$1.69M |
|
$1.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
24.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-171.10% |
|
-171.09% |
|
-164.15% |
|
-171.09% |
|
$0.12 |
|
$-0.59 |
|
$-0.59 |
|